A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
Recruiting · Phase 2 · NCT07269210
Conditions: Severe Hypertriglyceridemia
At a glance
- Research payments reported, 2025
- $2,817
- U.S. investigators named
- 9
- Sites paid
- 9
- Planned or actual enrollment
- 60
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Solbinsiran (drug), Placebo (drug)
- Dates
- Started 2025-12-08; completion 2027-08
- Results posted
- Not yet
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $2,817 in research payments for this study in 2025 (9 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alexis Gutierrez, M.D. Cardiology · Hialeah, FL
- Wael E. Eid, MD Endocrinology & Diabetes · Covington, KY
- Khanh-van T. Tran, M.D. Cardiology · Worcester, MA
- Sara D. Collins, M.D. Cardiology · Bowie, MD
- Samuel M. Kim Cardiology · New York, NY
- Eric J. Lawitz, M.D. Gastroenterology · San Antonio, TX
- Aditya K. Samal, MD Cardiology · Houston, TX
- Linda G. Schneider II, M.D. Family Medicine · Hampton, VA
- Savitha Subramanian Endocrinology & Diabetes · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Board of Regents of the Univ of Wisconsin Systm $313
- Elias Research Associates LLC $313
- Cardiovascular Specialists of Willowbrook $313
- St Elizabeth Edgewood, KY $313
- Weill Cornell Medical College $313
- The Texas Liver Institute $313
- Flourish Research Acquisition LLC $313
- Tpmg Rheumatology $313
- Univ of Massachusetts DBA Univ of Massachusetts $313
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.